Soleno Therapeutics Files 8-K

Ticker: SLNO · Form: 8-K · Filed: 2025-09-10T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, Regulation FD

TL;DR

SOLENO filed an 8-K today - likely a Reg FD disclosure, check for updates.

AI Summary

On September 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information that may be of interest to investors. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Soleno Therapeutics has made a disclosure under Regulation FD, which could contain important information for investors regarding company events or communications.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, with no immediate indication of significant negative or positive events.

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The provided excerpt does not specify the content of the Regulation FD disclosure; it only indicates that such a disclosure has been made.

When was this 8-K filing submitted?

The filing was submitted on September 10, 2025.

What is the primary business of Soleno Therapeutics, Inc.?

Soleno Therapeutics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].

What was the former name of Soleno Therapeutics, Inc.?

The former name of Soleno Therapeutics, Inc. was Capnia, Inc., with a date of name change on February 19, 2010.

Where are Soleno Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

From the Filing

0001193125-25-199882.txt : 20250910 0001193125-25-199882.hdr.sgml : 20250910 20250910123445 ACCESSION NUMBER: 0001193125-25-199882 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250910 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250910 DATE AS OF CHANGE: 20250910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251305266 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d88981d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-09-10 2025-09-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 10, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 7.01 Regulation FD Disclosure Soleno Therapeutics, Inc. is aware that a serious adverse event has been reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) regarding a patient who is deceased. The treating physician has reported the case as not related to treatment with VYKAT ™ XR and Soleno’s assessment is the same. This patient was a 17-year-old male with a history of co-morbidities, including lymphedema, superficial thrombophlebitis (treated and followed by a vascular surgery team), and obesity (326 lbs.) who died from an apparent pulmonary embolus. VYKAT XR has a proven safety and efficacy profile and was approved by the FDA following a rigorous clinical

View on Read The Filing